FY2018 EPS Estimates for Nightstar Therapeutics PLC (NITE) Boosted by Wedbush
Nightstar Therapeutics PLC (NASDAQ:NITE) – Investment analysts at Wedbush increased their FY2018 earnings estimates for shares of Nightstar Therapeutics in a research note issued to investors on Wednesday, November 14th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($1.48) for the year, up from their previous forecast of ($1.61). Wedbush currently has a “Outperform” rating and a $31.00 target price on the stock. Wedbush also issued estimates for Nightstar Therapeutics’ Q4 2018 earnings at ($0.40) EPS, FY2019 earnings at ($1.70) EPS, FY2020 earnings at ($1.72) EPS and FY2021 earnings at ($1.54) EPS.
Other analysts also recently issued reports about the company. Zacks Investment Research upgraded Nightstar Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 9th. Leerink Swann increased their price target on Nightstar Therapeutics from $30.00 to $35.00 and gave the stock a “positive” rating in a report on Monday, September 24th. Cantor Fitzgerald assumed coverage on Nightstar Therapeutics in a report on Thursday, October 11th. They set an “overweight” rating and a $36.00 price target for the company. Mizuho reiterated a “buy” rating and set a $20.00 price target on shares of Nightstar Therapeutics in a report on Tuesday, August 14th. Finally, Janney Montgomery Scott assumed coverage on Nightstar Therapeutics in a report on Wednesday, August 22nd. They set a “buy” rating and a $34.00 price target for the company. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $34.43.
Nightstar Therapeutics (NASDAQ:NITE) last issued its quarterly earnings results on Tuesday, November 13th. The company reported ($0.27) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.13.
Hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE bought a new position in shares of Nightstar Therapeutics during the 2nd quarter worth about $132,000. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Nightstar Therapeutics during the 3rd quarter worth about $169,000. Stanley Laman Group Ltd. bought a new position in shares of Nightstar Therapeutics during the 2nd quarter worth about $195,000. Janney Montgomery Scott LLC bought a new position in shares of Nightstar Therapeutics during the 3rd quarter worth about $204,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Nightstar Therapeutics during the 3rd quarter worth about $214,000. 25.49% of the stock is currently owned by institutional investors.
Nightstar Therapeutics Company Profile
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.
Further Reading: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.